Upload
lehanh
View
216
Download
2
Embed Size (px)
Citation preview
Figure 4
0 2 4 6 8 10 12 14
0
25
50
75
100
30[PDGF-BB] (ng/mL)
Per
cent
of m
axim
al E
RK
1/2
phos
phor
ylat
ion
-9 -8 -7 -60
25
50
75
100
log [dopamine]
Per
cent
of m
axim
al E
RK
1/2
phos
phor
ylat
ion
BA
lacZ + – + – + –C-truncPDGFRb – + – + – +
Treatment none 1 ng/mLPDGF-BB
3 nMdopamine
IP: FLAGIB: pTyr
IP: PDGFRbIB: PDGFRb
IB: PDGFRb-pY716
IB: PDGFRb-pY1021
IB: phospho-ERK1/2
IB: ERK1/2
lacZ + – + – + –C-truncPDGFRb – + – + – +
phospho-ERK1/2
phospho-ERK1/2
ERK1/2
ERK1/2
Treatment
Treatment
Pre-treatment
none
none
none
0.3 ng/mLPDGF-BB
3 nMdopamine
10 nM dopamine
DMSO tyrphostin A9
C-truncPDGFRb
PDGF-BB treatment
lacZ control
0
25
50
75
100
125
Per
cent
of p
hosp
ho-E
RK
sig
nal r
elat
ive
to la
cZ c
ontro
l
0.3 ng/mL(5)
1 ng/mL(6)
0
25
50
75
100
125
150C-truncPDGFRb
lacZ control
10 nM dopamine treatment
DMSO(4)
Tyrphostin A9(4)
pre- treatment,
Per
cent
of p
hosp
ho-E
RK
sig
nal
rela
tive
to la
cZ-tr
ansf
ecte
d,
DM
SO
pre
-trea
ted
cont
rol
dopamine treatment
Per
cent
of p
hosp
ho-E
RK
sig
nal r
elat
ive
to la
cZ c
ontro
l
0
25
50
75
100
125
150
3 nM(7)
10 nM(7)
C-truncPDGFRb
lacZ control
DlacZ + – + – + –C-truncPDGFRb – + – + – +
C
CHO/DRD4-PR
CHO/DRD4
CHO/DRD4